Why the study?
Does intravenous esmolol infused during cardiopulmonary bypass improve hemodynamics and myocardial protection without adverse clinical effects in patients undergoing cardiac surgery?
Population
30 patients scheduled for cardiopulmonary bypass (CPB)
Comparison
Intravenous esmolol vs Placebo
Design
RCT, randomized, double-blind
Follow-up
postoperative hospitalization
Authors
Loading...
Esmolol during CPB improves early post-bypass hemodynamics and myocardial protection without harm; extends evidence for intraoperative beta-blockade in cardiac surgery.
Does intravenous esmolol infused during cardiopulmonary bypass improve hemodynamics and myocardial protection without adverse clinical effects in patients undergoing cardiac surgery?
Esmolol infusion during cardiopulmonary bypass appears safe and is associated with improved early postoperative cardiac indices and lower lactate levels, without persistent negative inotropic or chronotropic effects.
Cork et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: